MLL rearrangement

Blood Cancer OncTalk: In this video, Drs. @MazieTsangMD, @myelomaMD, @sridevirajeeve, @AutumnJeong, and @AaronGoodman33 discuss the recent advancements of Revumenib and whether it can be used outside of KMT2A-Rearranged acute leukemia. https://t.co/QPBmOImt8S (@cancerGRACE)

Do you routinely do LP at diagnosis in asymptotic AML with high WBC, monocytic differentiation, FLT3 or MLL gene rearranged. https://t.co/KTH7BDVhd5 (recent paper on this issue) (@TalhaBadarMD)

Check out the article here: Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation https://t.co/CJoCODpFrT (@TaylorJ_MD)

Very interesting Is that an aml associated with mll rearrangment? Did the patient relapse on an ALL mode or is CD19 considered as an aberrant marker at relapse? (@saada_vsaada)

Revumenib Drives Durable CR/CRh Rates in KMT2A-rearranged and NMP1-mutant AML @ASH_hematology #leusm #ASH22 https://t.co/9cmwD20sO8 (@OncLive)

Nice paper about #MLL gene rearranged #MN 👉🏻 poor outcome 👉🏻 ⬆️tMN in MDS/cmml 👉🏻 ⬇️ comutations in MDS/cmml Biologic Features and Clinical Outcomes in Newly Diagnosed Myelodysplastic Syndrome with KMT2A rearrangements https://t.co/RJma3HXot4 (@AlkaliDr)

You realize you are conversing with two cancer doctors (one with expertise in treating pediatric leukemia) right? Enlighten me…what is the “root cause” of pediatric ALL? Does it apply to PH+ ALL, KMT2A-rearranged ALL, hypodiploid ALL and ALL harboring ETV6-RUNX1 fusions? (@SchlisK)

This is a very nonspecific statement. What “environment” allows KMT2A-rearranged leukemia to develop in infants for example? (@SchlisK)

Preclinical data of #HMA plus #VEN in #MLL rearranged #ALL. ⁦@LeukemiaJnl⁩ Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy | Leukemia https://t.co/gAopnWJwDy (@AlkaliDr)

https://t.co/rqTQcwauDw #ASH22 Trial in progress: Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m). (@TalhaBadarMD)

KMT2A-rearranged leukemia: the shapeshifter https://t.co/2CQMtSkIt9 #leusm (@BloodJournal)

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against #AML cells with MLL1 rearrangement or mutant NPM1 https://t.co/bCIgUycpt8 via @LeukemiaJnl #leusm @MDAndersonNews @Daver_Leukemia @DrKTakahashi (@DrHKantarjian)

Day 7: @BloodAdvances therapy-related ALL article by @CanerSaygin et al! #leusm -median OS 27 months -higher rates of KMT2A (MLL) rearrangement and MDS-like karyotype abnormalities https://t.co/QyKShRkQOC (@Anand_88_Patel)

#ASCO22 #leusm Uy: Menin inhibitors an important emerging therapy for NPM1 mutated or MLL (KMT2A) rearranged AML. Inhibit NPM1/Menin or KMT2A/Menin mediated transcription of Hox/Meis1 genes controlling leukemogenesis. (@hemedoc)

#ALFlive22 #leusm Armstrong: MLL rearrangement associated leukemias have a unique gene expression profile, linked to high level HoxA9 expr. Menin essential for transcription of subset of MLL targets. Menin inhibitor disrupts MLL and MLLr-partner mediated txn. (@hemedoc)

Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia | Nature Medicine https://t.co/E4P8yfYWNp (@weldeiry)

KMT2A rearrangement should be considered AML defining and be treated accordingly ! @ASH_hematology abstracts 👍🏻 #MedTwitter https://t.co/Z8VYsDUhKK (@nihardesai7)

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML - ⁦@CIBMTR⁩ https://t.co/FYYv1Z8lZH (@wlsaber)

Now we have menin inhibitors that should improve KMT2A (MLL) #leukemia outcome Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience @MDAndersonNews https://t.co/hCgNGL0lhO via @BloodAdvances | #leusm #ALL (@DrHKantarjian)

Outcomes of ALL with KMT2A (MLL) rearrangement - The MD Anderson Experience.https://t.co/WuZyC8gtgp @grichardmd @DrHKantarjian Dr.Jabbour @MDAndersonNews KMT2A rearrangements are ☠️in myeloid or lymphoid acute leuks #leusm @BloodAdvances (@drsangeetmd)

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A Rearranged AML: Results From the Phase III @COGorg Trial AAML0531 https://t.co/rJJRCz5VnB (@RabiHannaMD)

Dr yoshida KRAS in MLL Rearranged AML #ASH20 #ASH2020 (@SaudiLeukemia)